Wednesday, March 20, 2013

• Interview with Model N's CEO Zack Rinatat Forbes (Wed, Mar 20)
• Amgen Trains Herpes Virus to Shrink Skin Cancerat TheStreet (Wed, Mar 20)
• Amgen Reaches New 52-Week High (AMGN)at TheStreet (Wed, Mar 20)
• Hot Stock Minute: Sights On Cyprus, Homebuilder’s House on FireHot Stock Minute (Wed, Mar 20)
• Stocks To Watch: The FedEx Ship Slips, General Mills Bowls A StrikeHot Stock Minute (Wed, Mar 20)

Tuesday, March 19, 2013

• Down 60%: Affymax Cuts to the Boneat Motley Fool (Tue, Mar 19)
• Modified Cold Sore Virus Shrinks Melanoma Tumors, Amgen Saysat Forbes (Tue, Mar 19)
• Amgen's melanoma drug shows promise in key trialat Reuters (Tue, Mar 19)
• Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In MelanomaPR Newswire (Tue, Mar 19)
• Wisdom From John Templeton: How To Safeguard Wealth Against Turmoil And Inflationary Pressureat Seeking Alpha (Tue, Mar 19)
• Health Care Stocks On The Rise With Help From 5 Stocksat TheStreet (Tue, Mar 19)
• Revenue Management Company To Add An IPO To The Top Lineat Seeking Alpha (Tue, Mar 19)
• Fidelity manager says healthcare law, cuts will hit biotechat Reuters (Tue, Mar 19)
• Fidelity manager says healthcare law, cuts will hit biotechReuters (Tue, Mar 19)

Monday, March 18, 2013

• Affymax may file for bankruptcy; cuts 75 percent of workforceReuters (Mon, Mar 18)
• Drug maker Affymax to cut 230 workers, look at sale, bankruptcyat bizjournals.com (Mon, Mar 18)
• Amgen Inc (AMGN): Today's Featured Health Care Laggardat TheStreet (Mon, Mar 18)

Friday, March 15, 2013

• Does Amgen's Dividend Have Room to Soar?at Motley Fool (Fri, Mar 15)
• Amgen's Master Plan To Generate Biosimilar Blockbustersat Seeking Alpha (Fri, Mar 15)

Thursday, March 14, 2013

• Agilent And The Boom In Companion Diagnosticsat Seeking Alpha (Thu, Mar 14)
• Here's What a Fidelity ETF Might Look Likeat Barrons.com (Thu, Mar 14)

Wednesday, March 13, 2013

• Arena, Roche, And Amgen: Which Is The Best Bet?at Seeking Alpha (Wed, Mar 13)
• Is DaVita Worth a Buy?at Motley Fool (Wed, Mar 13)

Tuesday, March 12, 2013

• Smooth-Ride Investmentsat Motley Fool (Tue, Mar 12)
• Investors Must Wait to See if Merck Can Improve-Itat Motley Fool (Tue, Mar 12)

Add AMGN News to My Yahoo!